

Ref: 10/SE/LC/2024-25

Date: 06/05/2024

To,

**Head, Listing Compliance Department
BSE Limited**Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai - 400 001.**Scrip Code: 544122****Head, Listing Compliance Department
National Stock Exchange of India Limited**Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051**Scrip Symbol: ENTERO**

Dear Sir/Madam,

Subject: Outcome of Board Meeting**Reference: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ('LODR')**

With reference to the captioned subject matter, we would like to inform that the Board of Directors of Entero Healthcare Solutions Limited ("**Company**") has approved, inter-alia, to execute the definitive agreements to acquire 80% paid-up equity share capital of Avenir Lifecare Pharma Private Limited ("**ALPPL**") at their meeting held today i.e. 6th May 2024.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 are as under:

Sr. No.	Particulars	Details
a	Name of the target entity, details in brief such as size, turnover etc.	Avenir Lifecare Pharma Private Limited, a company incorporated in Hyderabad, Telangana, India, bearing CIN U46497TS2023PTC177827. ALPPL is engaged in the business of wholesale distribution of pharmaceuticals and other allied products. Paid-up equity share capital of ALPPL is Rs. 1,00,000/-

		The turnover of ALPPL for the financial year 2023-24 is NIL as ALPPL was incorporated as on October 9, 2023, and business operation did not commence during the financial year 2023-2024.
b.	whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm s length”	No, the acquisition shall not fall within related party transaction and promoter/promoter group/ group companies does not have any interest in the ALPPL.
c.	industry to which the entity being acquired belongs	ALPPL operates in same line of business activity i.e business of distribution of pharmaceuticals, surgical and other healthcare and allied products.
d.	objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The business of ALPPL is in line of the business of the Company i.e. wholesale distribution of pharmaceutical and other allied products and the acquisition of ALPPL by the Company shall enable the Company to expand its business in the State of Telangana and thereby enabling the Company to generate additional business and revenue on consolidated basis.
e.	brief details of any governmental or regulatory approvals required for the acquisition;	Not applicable.
f.	indicative time period for completion of the acquisition;	The acquisition shall be completed by 31 st May 2024.
G.	consideration whether cash consideration or share swap or any other form and details of the same	The acquisition of 8,000 equity shares of ALPPL will be through cash consideration.
h.	cost of acquisition and/ or the price at which the shares are acquired;	8,000 equity shares of ALPPL will be acquired at INR 10 (Indian Rupees Ten only) per equity

		share at total amount of Rs. 80,000/-. <i>Note: ALPPL has acquired three business undertakings as on April 10, 2024, as a going concern on a slump sale basis which are in the business of wholesale distribution of pharmaceutical products. The slump sale amount payable shall be discharged by ALPPL. Details are summarized in Annexure I.</i>
i	percentage of shareholding / control acquired and / or number of shares acquired;	Company is proposed to acquire 8,000 (eight thousand) equity shares of face value Rs. 10/- each equivalent to 80% (eighty percent) of the total issued and paid-up equity share capital of ALPPL.
j	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	ALPPL is engaged in the business of wholesale distribution of pharmaceutical and other allied products. ALPPL was incorporated on October 09, 2023. The turnover of ALPPL for the year 2023-24 is NIL. ALPPL conducts its business only in India.

The Board Meeting commenced at 3:30 PM (IST) and concluded at 6:15 PM (IST).

This is for your information and records.

Yours Faithfully
For **Entero Healthcare Solutions Limited**

Jayant Prakash
General Counsel, Company Secretary & Compliance Officer
(Mem: F6742)

Encl:

1. Annexure I

Annexure I

ALPPL has acquired three business undertakings as on April 10, 2024. Details of Revenue as mentioned below:

Figures in Rs. Mn

Name of the Firm	F.Y - 2023-2024 (9 months annualized)	F.Y - 2022-2023 (Actual)	F.Y - 2021- 2022 (Actual)
Lifecare Pharma Distributors- Hyderabad	313	240	316
Lifecare Pharma Distributors- Vizag	73	60	82
Sri Vasavi Medical Agencies- Hyderabad & Karimnagar	125	186	183
Total	511	486	581